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Abstract
Background: Approximately 20% of patients with ulcerative colitis become steroid dependent. Azathioprine is
recommended in steroid-dependent ulcerative colitis, but its side effects limit its use. Chinese herbal medicine has
been widely used to treat ulcerative colitis in China. However, its effectiveness in steroid-dependent patients has
not been evaluated. This study aims to investigate the efficacy of traditional Chinese medicine combination therapy
with 5-aminosalicylic acid in patients with steroid-dependent ulcerative colitis.
Methods/Design: This is a parallel, multicenter, randomized controlled trial. One hundred and twenty eligible
patients will be randomly assigned to a traditional Chinese medicine group or azathioprine group. All patients will
be given basic treatment, which includes steroids and 5-aminosalicylic acid. Patients allocated to the traditional
Chinese medicine group will receive basic treatment plus Chinese herbal medicine granules, while patients in the
azathioprine group will receive basic treatment plus azathioprine. The whole study will last 24 weeks. The primary
outcome measure is the steroid-free remission rate. Secondary outcome measures are health-related quality of life,
efficacy of endoscopic response, degree of mucosal healing, and inflammation indicators.
Discussion: Results from this study may provide evidence for the effectiveness of traditional Chinese medicine
combined with 5-aminosalicylic acid in patients with steroid-dependent ulcerative colitis. The findings will provide a
basis for further confirmatory studies.
Trial registration: Chinese Clinical Trial Register, ChiCTR-IPR-15005760. Registered on 2 January 2015.
Keywords: 5-aminosalicylic acid, Azathioprine, Chinese herbal medicine, Steroid-dependent ulcerative colitis, Study
protocol
Background
Ulcerative colitis is a form of inflammatory bowel disease
characterized by a chronic relapsing clinical course. Inter-
mittent rectal bleeding, diarrhea, and abdominal pain are
often symptoms of ulcerative colitis. 5-Aminosalicylic acid
is usually used in mild cases of ulcerative colitis. Steroids
are another effective therapy for inducing remission in pa-
tients with moderate and severely active ulcerative colitis.
Approximately 20–34% of patients with ulcerative colitis
have chronic active disease requiring several courses of
steroids to achieve remission [1, 2]. Many patients initially
benefit from steroid treatment but relapse shortly after
treatment cessation or after dose reduction. Up to 20% of
patients with ulcerative colitis become steroid dependent
[3]. The European Crohn’s and Colitis Organisation guide-
lines define “steroid-dependent” patients as those who are
unable to reduce steroids below the equivalent of prednis-
olone 10 mg/day within 3 months of starting steroid use,
without recurrent active disease, or who have a relapse
within 3 months of stopping steroid use [4]. The risks of
long-term steroid therapy include osteoporosis,
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pathological fractures, cataracts, metabolic changes,
psychological disturbances, and infection. Moreover,
steroids have not been shown to be effective for the
maintenance of remission.
The American College of Gastroenterology and Euro-
pean Crohn’s and Colitis Organisation guidelines recom-
mend that patients with steroid-dependent disease
should be treated with azathioprine or 6-mercaptopurine
[5, 6]. Azathioprine is significantly more effective than
5-aminosalicylic acid at achieving clinical and endo-
scopic remission in the treatment of steroid-dependent
ulcerative colitis. In a single-center retrospective cohort
study, 64 Asian patients with steroid-dependent inflam-
matory bowel disease were assessed, and 61% of patients
were able to maintain clinical remission after 5 years of
azathioprine therapy [7]. Toxicity induced by azathio-
prine and 6-mercaptopurine in patients with inflamma-
tory bowel disease includes bone marrow suppression,
drug-induced hepatitis, pancreatitis, and infection.
Complementary and alternative medicine use is com-
mon in patients with inflammatory bowel disease. The
single most commonly used modality in most surveys is
traditional Chinese medicine (TCM) [8]. Chinese herbal
medicine is useful in improving symptoms, such as ab-
dominal pain and diarrhea, and reducing inflammation
in patients with ulcerative colitis. Many steroid-
dependent patients are dissatisfied with conventional
therapies, including azathioprine’s side effects; thus, they
turn to TCM. However, it is not clear whether Chinese
herbal medicine is effective for patients with steroid-
dependent ulcerative colitis. Therefore, the primary aim
of our study is to evaluate the clinical efficacy of TCM
treatment among patients with steroid-dependent ul-
cerative colitis. Health-related quality of life in steroid-
dependent patients will be a secondary aim.
Methods/Design
This is a multicenter, randomized controlled trial with
two parallel groups and a 24-week follow-up. The cen-
ters include the Affiliated Hospital of Nanjing University
of Chinese Medicine, Beijing Hospital of Chinese Medi-
cine, Guangdong Province Hospital of Chinese Medi-
cine, Longhua Hospital affiliated to Shanghai University
of Chinese Medicine, the First Affiliated Hospital of
Henan University of Chinese Medicine, Nanjing Drum
Tower Hospital of Nanjing University of Medical School,
Shengjing Hospital of China Medical University, the
Hospital of Shanxi University of Chinese Medicine, the
First Affiliated Hospital of Heilongjiang University of
Chinese Medicine, and Nantong Hospital of Chinese
Medicine. The study began in January 2015 and will last
until October 2017. Trained researchers enroll partici-
pants. One hundred and twenty patients who meet the
eligibility criteria will be recruited and allocated into two
groups, with 60 individuals per group. This study has
been approved by the Institutional Review Board of Hu-
man Research of the Affiliated Hospital of Nanjing Uni-
versity of Chinese Medicine (approval number: 2014NL-
073-03). Participants must provide written informed
consent to participate in the study. All participants will
continue their initial steroid and 5-aminosalicylic ther-
apy, and will be randomly assigned to receive either
Chinese herbal medicine or azathioprine. The overall
flow of the trial is shown in Fig. 1.
Eligibility criteria
Participants will be considered for enrollment if they:
range in age from 18 to 65 years; have a confirmed diag-
nosis of steroid-dependent ulcerative colitis; agree to
participate in this clinical trial; and sign the informed
consent form.
Patients will be excluded from the study if they: ex-
perience complications such as intestinal obstruction, in-
testinal perforation, toxic megacolon, or colorectal
cancer; are pregnant, breast-feeding, or preparing for
pregnancy; have an alanine aminotransferase level above
the twice upper limit of normal; have a serum creatinine
level above the upper limit of normal; have a platelet
value of less than 50 × 109/l; have a leukocyte count of
less than 3.0 × 109/l; have a known history of alcohol or
drug abuse; or are enrolled in other clinical trials.
Sample size
The remission rate for ulcerative colitis by azathioprine
ranges from 59.1% to 87% [9, 10], and the average rate is
about 73%. This is a noninferiority trial. For a two-sided
significance level of 0.05 and power of 80% (α = 0.05, β
= 0.2, δ = 0.15), the sample size is calculated using the
formula:
n ¼ 12:365 P 1−Pð Þ=δ2
Considering a 10% loss to follow-up, the sample size is
120 cases (n = 60 in each group).
Randomization
A randomization sequence was generated using SAS
9.4 (SAS Institute Inc., Cary, NC, USA). An inde-
pendent person (Dr. Jiandong Zou) who is not involved
in observation or assessment of the patients possesses
the computer-generated randomization sequence. The
researchers are blinded to the randomization sequence.
The randomization procedure will be conducted by
research assistants using an online computerized ran-
domization system (https://sci.njpdkj.com/pdsci/). Eligible
participants will be randomly assigned to either the TCM
group or azathioprine group.
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Interventions
Basic treatment
All eligible steroid-dependent patients will continue
their initial steroid and 5-aminosalicylic therapy. With-
drawal of steroids occurs along with clinical remission. If
there is clinical remission, a taper dose will be initiated
with 5 mg taper weekly until a 20 mg daily dose is
reached. Then tapering should proceed by 2.5 mg per
week [11].
Chinese herbal medicine granules
Patients in the TCM group will be treated with basic
treatment plus granules. The granules include Radix As-
tragali (Huangqi) 20 g, Rhizoma Atractylodis Macroce-
phalae (Baizhu) 10 g, Semen Coicis (Yiyiren) 20 g,
Rhizoma Dioscoreae (Shanyao) 20 g, Rhizoma Coptidis
(Huanglian) 6 g, Radix Scutellariae (Huangqin) 10 g,
Radix Pulsatillae (Baitouweng) 10 g, Rhizoma Smilacis
Glabrae (Tufuling) 15 g, Radix Angelicae Dahuricae
(Baizhi) 12 g, Radix Paeoniae Alba (Baishao) 20 g, Peri-
carpium Citri Reticulatae (Chenpi) 12 g, Radix Saposh-
nikoviae (Fangfeng) 12 g, Radix Aucklandiae (Muxiang)
6 g, Radix Sanguisorbae (Diyu) 10 g, Radix Arnebiae
(Zicao) 10 g, Radix et Rhizoma Rubiae (Qiancao) 20 g,
Fructus Alpiniae Oxyphyllae (Yizhi) 10 g, Rhizoma Zin-
giberis Preparata (Paojiang) 6 g, and Radix et Rhizoma
Glycyrrhizae (Gancao) 6 g. All ingredients are manufac-
tured as a Chinese herbal granule with a weight 27.5 g
(Jiangyin Tianjiang Pharmaceutical Co., Ltd, Jiangyin,
China). Patients will take one Chinese herbal medicine
granule per day. The course of treatment is 24 weeks
unless there is a loss of follow-up.
Azathioprine
The control group will take basic treatment plus azathi-
oprine. Azathioprine treatment can be initiated at a dos-
age of 1 mg/kg per day [12, 13]. The course of treatment
will be in accordance with the TCM group.
Outcome measures
Primary outcome measure
The primary outcome measure of this study is the
steroid-free remission rate in patients with steroid-
dependent ulcerative colitis. Remission is defined as a
Fig. 1 Flow chart of the trial. 5-ASA, 5-aminosalicylic acid; AZA, azathioprine
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Mayo disease activity index score of 0–2, with no indi-
vidual subscore exceeding 1 [14]. The withdrawal time
of steroids will also be recorded. The outcome measure
will be evaluated at the end of 24 weeks. If there is no
statistical significance between the steroid-free remission
rate of the TCM group and the azathioprine group, then
the mean withdrawal time from steroids will be
compared.
Secondary outcome measures
The key secondary aim is to investigate the effect of
Chinese herbal medicine granules on health-related
quality of life in steroid-dependent patients compared
with azathioprine, as measured by the inflammatory
bowel disease questionnaire. Other secondary outcome
measures include the efficacy of endoscopic response,
which is defined as a decrease from baseline in a Mayo
disease activity index endoscopy subscore by at least 1
[14]. The degree of mucosal healing is defined as a Mayo
disease activity index endoscopy subscore of 0 or 1 [15].
Improvements in inflammation indicators include fecal
calprotectin, C reactive protein, and erythrocyte sedi-
mentation rate.
Adverse events
During the study, all adverse events, including toxicity
and side effects, such as drug allergies, liver damage,
renal failure, bone marrow suppression, and pancreatitis,
will be reported and recorded in the case report form in
detail. The researcher will report serious adverse events
to the Institutional Review Board of Human Research of
the Affiliated Hospital of Nanjing University of Chinese
Medicine.
Data management and statistical analysis
Data recorded in printed case report forms are kept in
locked cabinets. Data will be double-entered on elec-
tronic case report forms by two persons. Frequency, me-
dian, and mean ± standard deviation of the steroid-free
remission rate and the mean withdrawal time of steroids
will be used for descriptive statistics. Student’s t test and
analysis of variance will be employed using continuous
variables with a normal distribution. The Mann–Whit-
ney U test and Kruskal–Wallis test will be used for con-
tinuous variables with abnormal distributions, such as
health-related quality of life and inflammation markers.
A chi-square test or Fisher’s exact test will be used for
categorical variables, including the efficacy of endoscopic
response and the degree of mucosal healing. Results will
be analyzed as per intention-to-treat. All data will be an-
alyzed by an independent statistician using SAS 9.4. For
all analyses, P < 0.05 is considered statistically significant.
To summarize the present study protocol, please see
Additional file 1 for an overview of enrollment,
interventions and assessments, and Additional file 2 for
an overview of the Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) checklist.
Discussion
Ulcerative colitis is a chronic inflammatory bowel dis-
ease characterized by a relapsing-remitting course owing
to recurrent intestinal inflammation. Steroids are often
prescribed for moderate to severe ulcerative colitis pa-
tients. Although steroids are usually effective, long-term
steroid use should be avoided because of its severe side
effects. Patients who initially respond to steroids but
then relapse after tapering or shortly after discontinu-
ation, and require reintroduction of steroids to induce
remission are defined as steroid dependent. The thera-
peutic objective of steroid-dependent patients is to
achieve steroid-free remission.
In view of the side effects of steroids, different drugs
are used in the management of steroid-dependent ul-
cerative colitis. Drugs used include established agents,
such as thiopurines, methotrexate, infliximab, adalimu-
mab, vedolizumab, and golimumab. If common treat-
ments fail, colectomy may be performed [16]. Current
guidelines recommend thiopurines as first-line therapy
to spare steroids in steroid-dependent ulcerative colitis
[3, 6]. Therefore, the thiopurine agents azathioprine
and 6-mercaptopurine are used to sustain steroid with-
drawal in patients with steroid-dependent ulcerative
colitis [5]. Azathioprine is a purine analog that com-
petitively inhibits the biosynthesis of purine ribonucleo-
tides [17]. Azathioprine is the main therapy for steroid-
dependent patients in China, because vedolizumab and
golimumab are not available, and adalimumab is not in-
dicated for use in patients with ulcerative colitis. Fur-
thermore, cessation of infliximab is still considered in
clinical practice because of its high cost and fear of
long-term side effects [18]. There is also a reduced re-
sponse to infliximab, which may reach approximately
13% per year with uninterrupted scheduled mainten-
ance therapy [19]. Fraser et al. reported that the remis-
sion rate was 87% in 346 ulcerative colitis patients who
received more than 6 months of azathioprine treatment
[10]. Another study demonstrated that the steroid-free
remission rate was 59.1% in patients with steroid-
dependent or steroid-resistant ulcerative colitis treated
with azathioprine [9]. The most common adverse event
of azathioprine is leukopenia, which occurs in 3.8% of
patients [20]. Other adverse events include hepatitis,
infection, pancreatitis, and hair loss. Once absorbed
into the plasma, azathioprine is nonenzymatically
converted to 6-mercaptopurine. 6-Mercaptopurine can
be metabolized to 6-methylmercaptopurine by the en-
zyme thiopurine methyltransferase (TPMT), to 6-
thiouric acid by the enzyme xanthine oxidase, and to
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the active metabolites of 6-thioguanine nucleotide. 6-
Thioguanine nucleotide is the active ribonucleotide of
6-mercaptopurine; it functions as a purine antagonist,
resulting in immunosuppression and lymphocytotoxic-
ity. A deficiency in TPMT may lead to preferential 6-
mercaptopurine metabolism into 6-thioguanine nucleotide,
resulting in myelosuppression [21]. An apparent genetic
polymorphism of TPMT is associated with TPMT enzyme
deficiency. Despite a lower frequency of variant TPMT ob-
served in Asian populations [22], lower starting doses of
azathioprine are recommended in Asian populations than
in white populations, along with close monitoring of
complete blood count and liver function [13].
Chinese herbal medicine is a type of complementary
and alternative medicine, and is often used in patients
with inflammatory bowel disease [8], especially in China.
Dai et al. [23] analyzed 247 patients with ulcerative col-
itis. The Sutherland Disease Activity Index scores for pa-
tients treated with TCM and those treated with
integrated TCM and Western medicine were signifi-
cantly lower for both groups after treatment (P < 0.01).
Sugimoto et al. used the Chinese herbal medicine Qing-
Dai to treat 20 patients with moderate ulcerative colitis.
The rates of clinical response, clinical remission, and
mucosal healing were 72%, 33%, and 61% at week 8, re-
spectively [24]. Qing-Dai stimulates mucosal type 3 in-
nate lymphoid cells to generate interleukin-22, which
induces antimicrobial peptide and tight junction produc-
tion, suggesting a therapeutic mechanism for mucosal
healing [25]. Our study using Chinese herbal medicine
plus 5-aminosalicylic in patients with steroid-dependent
ulcerative colitis aims to observe improvements in the
primary outcome of steroid-free remission rate, and the
secondary outcomes of health-related quality of life,
endoscopic response, mucosal healing, and inflammation
indicators. We expect that the steroid-free remission
rate of the TCM group will be improved over that of the
azathioprine group. The mean withdrawal time of ste-
roids in the TCM groups should be less than that of the
azathioprine group, which would reduce the risks of
steroid therapy. We anticipate that the results will show
that Chinese herbal medicine is effective for patients
with steroid-dependent ulcerative colitis.
There are several limitations to our study. First, this is
an open-label randomized controlled trial without
double blinding. Because of the lack of placebo control
groups, our findings will be interpreted with caution.
Another limitation to this study is the lack of TPMT and
6-thioguanine nucleotide testing. Some patients do not
respond to azathioprine because of lower 6-thioguanine
nucleotide levels. Although a lower frequency of variant
TPMT is observed in Asian populations, TPMT and 6-
thioguanine nucleotide testing may assist dose
optimization of azathioprine to achieve response and
avoid drug-induced toxicity. Both TPMT and 6-
thioguanine nucleotide testing will be determined in cor-
ollary studies. The last limitation is of first-choice ther-
apy in steroid-dependent ulcerative colitis. The Toronto
consensus in 2015 recommends anti-TNF therapy to in-
duce and maintain complete steroid-free remission in
patients with steroid-dependent ulcerative colitis [26].
The consensus group also recommends that anti-TNF
plus azathioprine therapy is the preferred choice for
steroid-dependent patients rather than monotherapy to
induce complete remission [26, 27]. However, azathio-
prine is still the most practicable therapy for steroid-
dependent patients in China, because anti-TNF agents
are not widely used. Combination therapy with anti-TNF
agents will be available in the future. Notwithstanding
its limitations, this study will suggest whether Chinese
herbal medicine can be an effective complementary and
alternative medicine in patients with steroid-dependent
ulcerative colitis.
Trial status
The first patient in the study was enrolled on 24 April
2015. The trial is enrolling participants.
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